Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | BLM | P54132 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | WRN | Q14191 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21766262 | 0.87 | PTGS1 (0.38) | PTGS1PTGS2ALDH1A1HPGDTP53 | |
| SCHEMBL23339728 | 0.85 | KMT2A (0.35) | PTGS1PTGS2ALDH1A1HPGDTP53 | |
| SCHEMBL20763155 | 0.82 | MME (0.34) | PTGS1PTGS2 | |
| SCHEMBL2494888 | 0.81 | PTGS1 (0.40) | PTGS1PTGS2ALDH1A1HPGDTP53 | |
| SCHEMBL23339254 | 0.80 | MME (0.33) | PTGS1PTGS2 | |
| SCHEMBL20763230 | 0.79 | MME (0.32) | PTGS1PTGS2 | |
| SCHEMBL17453310 | 0.79 | PTGS1 (0.40) | PTGS1PTGS2ALDH1A1HPGDTP53 | |
| SCHEMBL20763356 | 0.78 | PTGS1 (0.37) | PTGS1PTGS2LMNAFOLH1PKM | |
| SCHEMBL21766059 | 0.77 | PTGS1 (0.39) | PTGS1PTGS2MAPK1 | |
| SCHEMBL17452207 | 0.77 | ALDH1A1 (0.36) | ALDH1A1HPGDCYP1A2BLMCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666623-B2 | Tetramaleimide linkers and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2023-06-06 | — | — | US | disclosed |
| US-20210388082-A1 | Anti-CD79b Antibodies, Drug Conjugates, and Applications Thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2021-12-16 | — | — | US | disclosed |
| US-20210128668-A1 | TETRAMALEIMIDE LINKERS AND USE THEREOF | NEWBIO THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20210128668-A1 | TETRAMALEIMIDE LINKERS AND USE THEREOF | NEWBIO THERAPEUTICS, INC. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10960082-B2 | Tridentate connexon and use thereof | NEWBIO THERAPEUTICS, INC. (CN) | 2021-03-30 | — | — | US | disclosed |
| EP-2949343-B1 | TRIDENTATE CONNEXON AND USE THEREOF | NEWBIO THERAPEUTICS INC (CN) | 2020-02-26 | — | — | EP | disclosed |
| WO-2019033773-A1 | TETRAMALEIMIDE LINKERS AND USE THEREOF | NEWBIO THERAPEUTICS, INC. (CN) | 2019-02-21 | — | — | WO | disclosed |
| US-20160015832-A1 | TRIDENTATE CONNEXON AND USE THEREOF | NEWBIO THERAPEUTICS, INC. (CN) | 2016-01-21 | — | — | US | disclosed |
| US-20160015832-A1 | TRIDENTATE CONNEXON AND USE THEREOF | NEWBIO THERAPEUTICS, INC. (CN) | 2016-01-21 | — | — | US | disclosed |
| EP-2949343-A1 | TRIDENTATE CONNEXON AND USE THEREOF | Newbio Therapeutics Inc. (CN) | 2015-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015832-A1 | TRIDENTATE CONNEXON AND USE THEREOF | DNTT, CD2, CD4 | PTGS1 4578/4885PTGS2 4792/4885ALDH1A1 2349/4885 |
| US-20210388082-A1 | Anti-CD79b Antibodies, Drug Conjugates, and Applications Thereof | FCGR2A, FCGR3B, CD99 | PTGS1 4729/4885PTGS2 4600/4885ALDH1A1 2522/4885 |
| US-10960082-B2 | Tridentate connexon and use thereof | DNTT, CD2, CLTA | PTGS1 4587/4885PTGS2 4795/4885ALDH1A1 2383/4885 |
| US-20210128668-A1 | TETRAMALEIMIDE LINKERS AND USE THEREOF | MCTS1, CA14, TTL | PTGS1 3928/4885PTGS2 4378/4885ALDH1A1 987/4885 |
| US-11666623-B2 | Tetramaleimide linkers and use thereof | MCTS1, CA14, TTL | PTGS1 3928/4885PTGS2 4378/4885ALDH1A1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.